EUR/USD
1.18038
-0.024%
Gold
4947.06
-0.375%
Oil
63.959
-0.425%
USD/JPY
156.868
-0.004%
GBP/USD
1.36479
-0.031%
GBP/JPY
214.095
-0.013%
Real-time News
On February 5th, shares of Qualcomm and Arm fell sharply after releasing their quarterly earnings reports, primarily due to market concerns that a shortage of memory chips would stifle growth in the electronics industry. In after-hours trading Wednesday evening, both companies shares dropped by more than 8%. Qualcomm, the largest manufacturer of smartphone processors, and Arm, which relies heavily on patent royalties from the mobile phone industry, both companies management teams signaled that supply constraints on memory chips would limit mobile phone production. The unprecedented expansion of artificial intelligence infrastructure is currently causing a shortage of memory chips, as these components help computers manage data. Manufacturers are currently focusing their production capacity on supplying AI data centers, resulting in insufficient production capacity for mobile phone components. This means fewer products will ultimately reach consumers, and at higher prices. Other companies have also sounded the alarm about a memory chip shortage. MediaTek stated in a conference call this week that the situation is "evolving." Intels CEO stated that the shortage could last for years, and suppliers have told him that the situation will not improve until 2028.Boeing (BA.N) plans to move engineering work on its 787 aircraft to South Carolina, and the Boeing engineers union is urging the company to provide more information about the move.February 5th - Everest Medicines (01952.HK), a Hong Kong-listed innovative pharmaceutical company, announced that it has signed an exclusive commercialization licensing agreement with McCormick, acquiring exclusive commercialization rights for its first-in-class dual-target peptide drug MT1013 in China and the Asia-Pacific region (excluding Japan). According to the agreement, Everest Medicines will pay McCormick an upfront payment of RMB 200 million, plus potential regulatory and commercial milestone payments of up to RMB 1.04 billion. Phase III clinical trials in China are currently underway, and related clinical development costs will be borne by McCormick.A chart summarizing the overnight price movements of international spot platinum and palladium.The Japanese government announced that TSMC (TSM.N) CEO C.C. Wei will visit the office of Japanese Prime Minister Sanae Takaichi at 02:00 GMT (10:00 Beijing time).
